Teva and Active Biotech Announce CONCERTO trial of Laquinimod trial fails
The top 10 leading biotech companies | biotechworldwide.net
Teva Pharmaceutical Industries Ltd - News, Articles etc. - European Pharmaceutical Review
PharmaShots | Incisive News in 3 Shots
Tweets with replies by Teva Pharmaceuticals (@TevaUSA) / Twitter
Teva: Leverage A Concern (NYSE:TEVA) | Seeking Alpha
Teva, Active Biotech enrol first patient in RRMS drug Phase III study - Clinical Trials Arena
Active Biotech's partner Teva starts laquinimod clinical trial
Teva - Smart Woman Securities
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Active Biotech provides update on laquinimod in Huntington's disease - Huntington's Disease News
Teva drops laquinimod for most common form of MS after failed trial - PMLiVE
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
2nd Annual NASDAQ TASE Israeli Investor Conference Dan Suesskind, CFO Teva Pharmaceutical Industries Ltd. November 27, ppt download
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
Active Biotech Pivots Away from MS and Huntington's Disease, Goes in New Direction | BioSpace
Active Biotech Regains Rights to Laquinimod from Teva, Plans to Continue Work on Potential MS Oral Therapy
Teva recalls US-made drugs following contamination fears - The Boston Globe
Active Biotech - News, Articles etc. - European Pharmaceutical Review
Active Biotech and Teva remain committed to clinical development program for multiple sclerosis
Active Biotech Regains Rights Over Laquinimod from Teva Pharmaceutical
